Coronary artery disease (CAD) is the largest single cause of death in Australia and acute coronary syndrome (ACS) is responsible for much of its mortality and morbidity burden. ACS is usually due to rupture of high risk (HRP), inflamed but non-obstructive atherosclerotic plaque. Despite optimal lipid lowering therapy, patients with residual inflammatory risk still develop recurrent ACS. There is therefore a need for a non-invasive modality that can detect vascular inflammation and assess plaque morphology. Pericoronary fat attenuation index (FAI) is a new computed-tomography- coronary-angiography (CCTA) derived novel imaging biomarker which captures coronary inflammation by mapping spatial changes of pericoronary fat attenuation.
The advancement of CCTA provides an accurate and reproducible imaging tool by which HRP can be detected, characterised and quantified non-invasively and serially over time. I am an interventional cardiologist who is an international expert in CCTA assessment of:
I had recently demonstrated that plaque progression assessment on CCTA is comparable to intravascular ultrasound (IVUS). My research will assess:
Two pronged research aimed to 1) identify novel biomarkers for early detection of CAD; and 2) test the health and economic impact of applying polygenic risk scores to individuals deemed to be at low risk by traditional algorithms
Position statement: Coronary artery calcium scoring for the primary prevention of cardiovascular disease in Australia.
Coronary heart disease (CHD) or coronary artery disease occurs when a coronary artery clogs and narrows because of a buildup of plaque
Last updated12 July 2021